INO - Inovio Pharmaceuticals Inc Stock Price, Fair Value and News

10.57USD+0.44 (+4.34%)Market Closed

Market Summary

USD10.57+0.44

Market Closed

4.34%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

247.0M

Price/Earnings (Trailing)

-1.83

Price/Sales (Trailing)

50.76

EV/EBITDA

-1.77

Price/Free Cashflow

-1.98

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-2776.48%

Return on Equity

-115.14%

Return on Assets

-79.04%

Free Cashflow Yield

-50.48%

INO Fundamentals

INO Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

-17.66%

Rev. Growth (Qtr)

-73.57%

INO Earnings

Earnings (TTM)

-135.1M

Earnings Growth (Yr)

54.09%

Earnings Growth (Qtr)

26.31%

Breaking Down INO Revenue

Last 7 days

-0.8%

Last 30 days

-18.3%

Last 90 days

64.6%

Trailing 12 Months

4.1%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

3.6

INO Investor Care

Shares Dilution (1Y)

7.81%

Diluted EPS (TTM)

-6.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.3M	13.7M	4.9M	4.9M
2022	2.7M	2.7M	11.5M	10.8M
2021	8.3M	8.2M	7.6M	2.8M
2020	2.6M	3.5M	3.6M	8.9M
2019	31.8M	7.5M	6.3M	4.1M
2018	39.3M	36.4M	33.4M	30.5M
2017	37.6M	51.8M	41.9M	42.2M
2016	43.5M	44.4M	32.8M	35.4M
2015	13.3M	14.8M	37.1M	40.6M
2014	14.4M	17.4M	9.7M	10.5M
2013	3.9M	4.2M	12.9M	13.5M
2012	8.4M	6.4M	4.6M	4.1M
2011	7.9M	9.2M	10.5M	9.8M
2010	0	8.1M	7.1M	6.1M
2009	0	0	0	9.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Inovio Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	humeau laurent	sold (taxes)	-19,184	8.16	-2,351	chief scientific officer
Feb 26, 2024	shea jacqueline elizabeth	sold (taxes)	-30,420	8.16	-3,728	chief executive officer
Feb 26, 2024	kies peter	sold (taxes)	-28,282	8.16	-3,466	cfo
Feb 26, 2024	kies peter	acquired	-	-	5,875	cfo
Feb 26, 2024	weiner david b.	acquired	-	-	2,916	-
Feb 26, 2024	humeau laurent	acquired	-	-	5,734	chief scientific officer
Feb 26, 2024	shea jacqueline elizabeth	acquired	-	-	7,731	chief executive officer
Jun 30, 2023	sumner michael john	acquired	-	-	35,000	chief medical officer
Jun 05, 2023	zoth lota s.	sold	-3,192	0.56	-5,700	-
May 16, 2023	zoth lota s.	acquired	-	-	19,000	-

Which funds bought or sold INO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	92,000	92,000	-%
Apr 25, 2024	Allworth Financial LP	sold off	-100	-192	-	-%
Apr 25, 2024	Bogart Wealth, LLC	sold off	-100	-3.00	-	-%
Apr 25, 2024	Allworth Financial LP	new	-	431	431	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-5,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-66,855	-	-%
Apr 24, 2024	Arlington Capital Management, Inc.	sold off	-100	-14,145	-	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	sold off	-100	-10,000	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-2,040	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	new	-	4,622	4,622	-%

Are Funds Buying or Selling INO?

Are funds buying INO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INO

No. of Funds

Unveiling Inovio Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.24%	19,766,042	SC 13G/A
Jan 22, 2024	state street corp	0.32%	871,047	SC 13G/A
Jul 10, 2023	state street corp	0.33%	877,447	SC 13G/A
Jul 07, 2023	blackrock inc.	2.3%	6,086,623	SC 13G/A
Feb 09, 2023	state street corp	12.61%	31,472,352	SC 13G/A
Feb 09, 2023	vanguard group inc	6.83%	17,042,500	SC 13G/A
Jan 24, 2023	blackrock inc.	9.3%	23,284,119	SC 13G/A
Apr 11, 2022	state street corp	10.49%	23,267,928	SC 13G/A
Feb 11, 2022	state street corp	6.32%	13,300,430	SC 13G/A
Feb 01, 2022	blackrock inc.	8.7%	18,244,914	SC 13G/A

Recent SEC filings of Inovio Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-K	Current Report
Apr 17, 2024	424B5	Prospectus Filed
Apr 15, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Mar 06, 2024	10-K	Annual Report
Feb 28, 2024	4	Insider Trading
Feb 28, 2024	4	Insider Trading
Feb 28, 2024	4	Insider Trading
Feb 28, 2024	4	Insider Trading
Feb 28, 2024	4	Insider Trading

Peers (Alternatives to Inovio Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-1.15%	-18.78%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-5.46%	-27.26%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-6.36%	-11.66%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.50%	-30.40%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.4B	-	-18.25%	70.26%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.32%	-19.69%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.79%	-8.36%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.14%	-47.54%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-7.41%	335.24%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.26%	4.12%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Inovio Pharmaceuticals Inc News

Latest updates

Inovio Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-73.6%	102,651	388,446	2,168,233	2,207,171	124,666	9,154,133	857,667	669,814	839,115	291,698	928,111	769,237	5,580,581	896,710	1,067,399	1,327,274	279,488	866,863	135,674	2,829,905	2,502,624
Operating Expenses	-23.5%	27,496,391	35,941,458	37,267,068	44,067,121	56,070,821	44,911,177	104,921,721	71,932,069	106,347,454	60,244,852	83,474,759	52,925,612	34,920,019	36,565,618	33,448,085	26,559,542	30,700,541	24,818,650	28,336,367	31,364,917	32,001,788
S&GA Expenses	3.2%	10,243,341	9,925,055	13,523,098	13,890,610	13,950,944	11,824,047	48,456,836	15,953,458	14,048,635	13,156,183	12,666,341	13,881,194	8,617,458	10,110,506	11,071,510	7,448,354	8,696,586	5,681,441	5,850,101	6,975,029	5,636,141
R&D Expenses	11.3%	17,253,050	15,503,032	23,743,970	30,176,511	42,119,877	33,087,130	56,464,885	55,978,611	92,298,819	47,088,669	70,808,418	39,044,418	26,302,561	26,455,112	22,376,575	19,111,188	22,003,955	19,137,209	22,486,266	24,389,888	26,365,647
EBITDA Margin	17.8%	-26.98	-32.81	-12.01	-19.18	-25.24	-28.21	-130	-117	-105	-28.19	-16.00	-20.98	-	-	-	-	-	-	-	-	-
Interest Expenses	-9.9%	282,325	313,488	313,488	313,488	313,488	313,488	313,488	313,488	480,313	476,374	466,726	513,034	1,068,008	1,984,046	2,846,641	2,803,755	2,668,837	2,428,671	2,194,783	656,248	-156,261
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-87,764	-	-106,771	-62,800	-
Earnings Before Taxes	26.3%	-25,003,638	-33,929,864	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-76,908,506	-106,947,580	-60,169,041	-82,139,958	-53,967,744	-22,415,201	20,931,010	-128,270,709	-33,135,404	-38,235,146	-23,536,452	-29,685,847	-29,351,667	-32,962,205
EBT Margin	17.5%	-27.76	-33.67	-12.34	-19.56	-25.69	-28.66	-132	-119	-107	-28.89	-16.83	-22.10	-	-	-	-	-	-	-	-	-
Net Income	26.3%	-25,003,638	-33,929,864	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-79,073,719	-106,947,580	-60,169,041	-82,139,958	-54,402,131	-24,338,380	19,171,336	-129,172,466	-33,135,404	-37,662,038	-23,090,693	-29,387,226	-29,219,262	-32,962,205
Net Income Margin	17.5%	-27.76	-33.66	-12.33	-19.55	-25.89	-28.84	-133	-120	-107	-29.20	-17.34	-22.70	-	-	-	-	-	-	-	-	-
Free Cashflow	9.7%	-26,275,785	-29,110,632	-32,338,571	-36,961,461	-36,505,141	-67,552,146	-51,245,185	-61,882,102	-38,534,821	-46,659,317	-78,667,141	-53,078,252	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.5%	171	193	233	267	349	392	459	446	496	536	592	655	540	438	443	339	144	152	165	191	131
Current Assets	-12.4%	153	175	203	234	315	350	416	400	448	487	542	588	471	377	382	276	94.00	99.00	111	135	88.00
Cash Equivalents	-23.9%	14.00	19.00	53.00	28.00	46.00	22.00	41.00	59.00	71.00	68.00	59.00	84.00	251	179	215	158	22.00	16.00	20.00	21.00	24.00
Net PPE	-11.9%	5.00	6.00	6.00	7.00	8.00	16.00	16.00	17.00	17.00	18.00	18.00	11.00	11.00	11.00	11.00	12.00	13.00	14.00	14.00	15.00	16.00
Goodwill	-	-	-	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00
Liabilities	-2.4%	54.00	55.00	64.00	67.00	126	125	162	90.00	96.00	82.00	83.00	73.00	79.00	114	257	151	139	115	109	110	44.00
Current Liabilities	-2.6%	43.00	44.00	52.00	55.00	97.00	95.00	131	59.00	66.00	51.00	52.00	42.00	42.00	41.00	38.00	32.00	32.00	20.00	24.00	27.00	35.00
Long Term Debt	-	-	-	-	-	17.00	16.00	17.00	16.00	15.00	14.00	15.00	14.00	5.00	4.00	14.00	13.00	64.00	8.00	63.00	61.00	-
LT Debt, Current	1.7%	17.00	16.00	17.00	16.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	17.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-15.1%	117	138	169	199	222	267	298	355	400	454	509	582	461	324	186	188	5.00	36.00	56.00	81.00	87.00
Retained Earnings	-1.4%	-1,622	-1,600	-1,600	-1,500	-1,487	-1,433	-1,395	-1,287	-1,209	-1,102	-1,042	-960	-906	-881	-901	-772	-739	-702	-679	-649	-620
Additional Paid-In Capital	0.3%	1,741	1,737	1,734	1,728	1,711	1,701	1,694	1,642	1,610	1,557	1,551	1,542	1,367	1,206	1,088	958	743	735	732	727	708
Shares Outstanding	3.7%	23.00	22.00	22.00	22.00	21.00	21.00	20.00	18.00	17.00	17.00	17.00	17.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	4.00	2.00	2.00	3.00	3.00	0.00
Float	-	-	-	120	-	-	-	426	-	-	-	1,900	-	-	-	4,200	-	-	-	280	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	9.7%	-26,275	-29,110	-32,314	-36,664	-36,340	-67,465	-50,527	-61,882	-37,891	-46,490	-78,459	-52,867	-51,216	-74,158	-27,151	-25,452	-13,737	-27,733	-23,924	-32,454	-17,281
Share Based Compensation	9.0%	2,266	2,079	2,918	3,809	3,274	3,234	8,336	7,711	5,474	5,620	5,646	9,596	3,825	4,158	3,662	4,002	2,034	2,080	3,355	3,433	2,138
Cashflow From Investing	463.0%	19,943	-5,493	53,907	19,000	54,001	44,557	-10,304	21,332	-6,493	55,958	50,306	-275,115	-3,716	39,115	-42,385	-51,808	10,435	8,270	21,588	-49,337	7,183
Cashflow From Financing	163.1%	1,838	699	2,883	-424	6,668	3,812	42,939	28,422	47,595	-440	3,441	160,903	126,939	-1,695	126,523	213,513	9,645	15,581	1,294	78,877	14,394

INO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Revenues [Abstract]

Revenue from collaborative arrangements and other contracts, including affiliated entity

$ 832,010

$ 10,262,268

$ 1,774,758

Operating expenses:

Research and development

86,676,563

187,650,503

249,240,324

General and administrative

47,582,104

90,185,285

53,752,353

Impairment of goodwill

10,513,371

Total operating expenses

144,772,038

277,835,788

302,992,677

Loss from operations

(143,940,028)

(267,573,520)

(301,217,919)

Other income (expense):

Interest income

8,133,290

4,782,030

3,363,080

Interest expense

(1,222,789)

(1,253,952)

(1,936,447)

Gain (loss) on investment in affiliated entity

773,145

(1,899,654)

(553,570)

Net unrealized gain (loss) on available-for-sale equity securities

5,850,626

(7,846,172)

(3,222,838)

Other (expense) income, net

(4,711,596)

(3,861,584)

343,371

Net loss before share in net loss of Geneos

(135,117,352)

(277,652,852)

(303,224,323)

Share in net loss of Geneos

(2,165,213)

(434,387)

Net loss

$ (135,117,352)

$ (279,818,065)

$ (303,658,710)

Net loss per share

Basic (in dollars per share)

^[1]

$ (6.09)

$ (14.07)

$ (17.45)

Diluted (in dollars per share)

^[1]

$ (6.09)

$ (14.07)

$ (17.45)

Weighted average number of common shares outstanding

Basic (in shares)

^[1]

22,173,662

19,885,182

17,402,483

Diluted (in shares)

^[1]

22,173,662

19,885,182

17,402,483

[1]	(1) Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.

INO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 14,310,862

$ 46,329,359

Short-term investments

130,982,913

206,669,397

Prepaid expenses and other current assets

5,393,665

50,130,481

Prepaid expenses and other current assets from affiliated entities

20,432

375,227

Total current assets

153,113,100

315,242,680

Fixed assets, net

4,960,986

7,727,997

Investments in affiliated entity

2,780,287

2,007,142

Intangible assets, net

2,129,861

Goodwill

10,513,371

Operating lease right-of-use assets

9,491,735

10,228,207

Other assets

605,315

684,044

Total assets

170,951,423

348,533,302

Current liabilities:

Accrued clinical trial expenses

2,365,382

10,594,073

Operating lease liability

2,406,522

2,803,973

Grant funding liability

87,489

2,475,031

Grant funding liability from affiliated entities

21,918

87,673

Convertible senior notes

16,770,654

Total current liabilities

42,570,228

96,868,074

Convertible senior notes

16,614,840

Operating lease liability, net of current portion

11,032,066

12,655,586

Deferred tax liabilities

32,046

Total liabilities

53,602,294

126,170,546

Commitments and contingencies

Inovio Pharmaceuticals, Inc. stockholders’ equity:

Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2023 and 2022

Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022

^[1]

22,792

21,090

Additional paid-in capital

1,740,954,074

1,710,888,191

Accumulated deficit

(1,622,965,136)

(1,487,847,784)

Accumulated other comprehensive loss

(662,601)

(698,741)

Total Inovio Pharmaceuticals, Inc. stockholders’ equity

117,349,129

222,362,756

Total liabilities and stockholders’ equity

170,951,423

348,533,302

Nonrelated Party

Current assets:

Accounts receivable

1,701,726

Current liabilities:

Accounts payable and accrued expenses

19,847,744

79,686,885

Related Party

Current assets:

Accounts receivable

2,405,228

10,036,490

Current liabilities:

Accounts payable and accrued expenses

$ 1,070,519

$ 1,220,439

[1]

(1) The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock.Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024.Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jacqueline E. Shea Ph.D.
WEBSITE	inovio.com
INDUSTRY	Biotechnology
EMPLOYEES	135

Inovio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Thu Apr 25 2024, market cap of Inovio Pharmaceuticals Inc is 236.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers. The fair value of Inovio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inovio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, INO's PE ratio (Price to Earnings) is -1.75 and Price to Sales (PS) ratio is 48.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.214 (multiply by 100 for percentage) rate of return.